Author's response to reviews

Title: Topical Clobetasol for the Treatment of Toxic Epidermal Necrolysis: Study Protocol for a Phase II Split-Body Randomized Placebo-Controlled Trial

Authors:

Reason Wilken (reason.wilken@gmail.com)
Chin-Shang Li (cssli@ucdavis.edu)
Victoria R Sharon (Victoria.sharon@ucdmc.ucdavis.edu)
Falin B Patel (Falin.patel@gmail.com)
Forum Patel (patelforumb@gmail.com)
Emanual Maverakis (emaverakis@ucdavis.edu)

Version: 2
Date: 8 January 2015

Author's response to reviews: see over
Dear Trials,

Attached is a revised version of our article “Topical clobetasol for the treatment of toxic epidermal necrolysis: study protocol for a randomized controlled trial” (MS # 1149667164138970). We have received the email communication of requested formatting changes and they have been addressed in the manuscript as listed below:

1. **Title:** Altered to “Topical clobetasol for the treatment of toxic epidermal necrolysis: study protocol for a randomized controlled trial” to conform to journal format.

2. **Funding statement:** Removed from title page.

3. **Financial Disclosures:** Moved to Acknowledgements section.

4. **Abstract:** Added after title page.

5. **IRB Approval number added to the Ethical Approval section.** The final IRB approval letter dated December 4\textsuperscript{th} 2014 is also attached as a PDF. This approval is considered final and is not conditional.

6. **Duplicate Author Contributions:** Corrected to reflect all authors with initials and contributions.

7. **Funding Documentation:** Award letter from Burroughs Wellcome Fund attached as verification.

Thank you for your review of our resubmitted protocol and please do not hesitate to contact us with any further questions.

Sincerely,

Emanuol Maverakis, M.D.
University of California, Davis School of Medicine
Department of Dermatology- Associate Professor
3301 C Street, Suite 1400
Sacramento, CA 95816
Telephone (916) 843-7336